Notice of Results

RNS Number : 1604R
Advanced Medical Solutions Grp PLC
17 August 2010

For Immediate Release: 17 August 2010


Advanced Medical Solutions Group plc

(“AMS” or “the Company”)


Notification of Interim Results


Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, will announce its interim results for the six months ended 30 June 2010 on Wednesday 8 September 2010.


A briefing for analysts will be held at 9.30am on the day of the results at the offices of Tavistock Communications, 131 Finsbury Pavement, London EC2A 1NT



ends –


For further information, please visit or contact:


Advanced Medical Solutions Group plc

Don Evans, Chief Executive Officer                                                         Tel: +44 (0) 1606 545508

Chris Meredith, Chief Operating Officer

Mary Tavener, Finance Director


Tavistock Communications

John West / Andrew Dunn / Chris Munden                                                Tel: +44 (0) 20 7920 3150


Investec Bank plc

Gary Clarence / Daniel Adams                                                                Tel: +44 (0) 20 7597 5970



Notes to Editors:


AMS advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foams. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids and provide an optimal environment for healing to occur. Silver is widely recognised as a safe and effective broad-spectrum anti-microbial agent for infection control.


AMS wound closure and sealants products are based on cyanoacrylate adhesive (“superglue”) technology developed for medical applications. Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incision. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes. The technology is also ideally suited to protecting skin from breakdown or for use as a skin sealant to help prevent infection of surgical sites.


AMS employs 240 people in three locations (Winsford, Plymouth and the Netherlands). In 2009, AMS delivered a 19% increase in revenues and a 51% increase in operating profit before exceptionals. The business has an experienced management team, whose stated aim is to grow the business both organically and by exploring selective acquisition opportunities. The Board has announced its intention to recommend a maiden dividend for the year ended 31st December 2010.


This information is provided by RNS
The company news service from the London Stock Exchange